JD Health doubles profit, boosts omnichannel strategy in 2024

** JD Health International Inc. (HKEX: 6618) announced a significant increase in profitability for the year ended December 31, 2024, with profit soaring to RMB4.2 billion, a 94% increase compared to RMB2.1 billion in 2023. Revenue also increased by 8.6% to RMB58.2 billion. This growth was underpinned by strong performance in both its direct sales and online marketplace businesses, with a focus on deepening cooperation with pharmaceutical companies and expanding product offerings. A core element of JD Health's success was its strategic advancement of its omnichannel presence. This includes upgrading its instant delivery service, expanding medical insurance reimbursement for online purchases to 18 cities, and the launch of offline JD Pharmacy stores in Beijing. Looking ahead, JD Health is solidifying its partnership with JD.com through a Receivables Management Framework Agreement, to manage its consumer financing receivables and accelerate working capital efficiency. Furthermore, the Company is focused on its AI initiatives.